Halozyme Therapeutics company profile

HALO · NASDAQ · USD

Compare Halozyme Therapeutics
$95.97Change from previous close: −0.55%Absolute change: −$0.53

Close · November 17, 2026

Company profile

Halozyme Therapeutics has 423 employees and is headquartered in San Diego, United States.

Halozyme is known for Hylenex and XYOSTED, and for its patented recombinant human hyaluronidase enzyme, rHuPH20, which lets injectable biologics be delivered under the skin. Its partners market subcutaneous versions of well-known cancer, autoimmune and immunodeficiency therapies, including Herceptin Hylecta, Phesgo, Tecentriq SC, Ocrevus SC, HYQVIA and DARZALEX, and the company also works with argenx, Pfizer, AbbVie and Eli Lilly. Its licensing collaborations and its own proprietary enzymes and devices reach markets in the United States, Switzerland, Belgium, Japan and beyond.

In the fiscal year ended December 2025, Halozyme reported revenue of USD 1.4 billion, up 37.6% from the previous year, and net income of USD 316.9 million. The company had 423 employees and is headquartered in San Diego, California, where it was founded in 1998. Its shares also trade on other exchanges.

Company facts

Industry
Biotechnology
Headquarters
12390 El Camino Real, 92130, San Diego
Employees
423
Chief executive
Helen Torley
Founded
1998
Fiscal year
January - December
Listing
HALO · NASDAQ
Currency
USD
ISIN
US40637H1095

Halozyme Therapeutics and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Halozyme TherapeuticsHALOUnited States$14.67B42356.8%38.3
BridgeBio PharmaBBIOUnited States$15.25B1,081-37.3%—
Jazz PharmaceuticalsJAZZUnited States$15.5B2,89027.4%71.5
ExelixisEXELUnited States$16.37B1,07740.2%20.1
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
Bio-TechneTECHUnited States$11.43B3,00021.7%66.8

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Halozyme Therapeutics with its competitors